Englebert Financial Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Englebert Financial Advisers's VRTX Position: Q2 2026 in Review
Englebert Financial Advisers opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 428 shares worth $213K. The stake represents 0.21% of the portfolio and ranks #61 among its holdings. This is a return to the name: Englebert Financial Advisers previously reported a position in VRTX as recently as Q4 2025.
Englebert Financial Advisers first reported a position in VRTX in Q4 2025 and has held it in 2 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Englebert Financial Advisers held 428 shares of Vertex Pharmaceuticals worth $213K as of Q2 2026.
- Vertex Pharmaceuticals was a new Englebert Financial Advisers position in Q2 2026.
- Vertex Pharmaceuticals made up 0.21% of Englebert Financial Advisers's portfolio in Q2 2026, its #61 holding.
- Englebert Financial Advisers first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Englebert Financial Advisers's 13F filing for Q2 2026, filed 22 Jul 2026.